Pacira BioSciences (NASDAQ:PCRX) SVP Sells $143,702.50 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at $1,463,674. This trade represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pacira BioSciences Stock Performance

PCRX stock traded down $0.37 during mid-day trading on Friday, reaching $22.99. 371,248 shares of the stock traded hands, compared to its average volume of 408,642. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $27.64. The business has a 50-day moving average of $23.58 and a two-hundred day moving average of $23.27. The firm has a market capitalization of $904.66 million, a PE ratio of 191.60 and a beta of 0.29.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The firm had revenue of $177.38 million for the quarter, compared to the consensus estimate of $171.80 million. During the same quarter last year, the company earned $0.65 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. As a group, equities analysts predict that Pacira BioSciences, Inc. will post 1.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PCRX shares. Royal Bank Of Canada increased their target price on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research note on Friday, May 1st. Barclays reduced their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Weiss Ratings upgraded shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Finally, Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $29.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. increased its holdings in shares of Pacira BioSciences by 15.1% in the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after purchasing an additional 492 shares in the last quarter. Inspire Investing LLC increased its holdings in shares of Pacira BioSciences by 3.2% in the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after purchasing an additional 556 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after purchasing an additional 721 shares in the last quarter. State of Wyoming increased its holdings in shares of Pacira BioSciences by 7.0% in the fourth quarter. State of Wyoming now owns 11,155 shares of the company’s stock valued at $289,000 after purchasing an additional 728 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Pacira BioSciences by 8.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company’s stock valued at $259,000 after purchasing an additional 785 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.